Hikal Limited share price
NSE: HIKAL · ISIN INE475B01022
Key numbers
- Market cap
- ₹ 2,683 Cr
- Current price
- ₹ 217.58
- 52-week high / low
- ₹ 261 / 146
- Stock P/E
- -
- Book value
- ₹ 97.2
- Dividend yield
- 0.28%
- ROCE
- -0.9%
- ROE
- -4.0%
- Debt to equity
- 0.57
- Sales growth (3 yrs)
- -5.4%
- Profit growth (3 yrs)
- -
- 1-year return
- -16.3%
About Hikal Limited
Hikal Limited, together with its subsidiaries, manufactures and sells various chemical intermediates, specialty chemicals, and active pharma ingredients to pharmaceutical, biotechnology, life sciences, animal health, crop protection, and specialty chemicals indusries. It operates through two segments, Pharmaceuticals and Crop Protection. The company also manufactures pesticides and herbicides, which include diuron tech, temephos tech, thiacloprid tech, clothianidin tech, dichloroaniline, N-bromosuccinimide, prothioconazole technical, trifloxystrobin technical, and BIT. In addition, it offers solutions in contract research, custom synthesis, and custom manufacturing of intermediates and active ingredients. Further, the company provides anti-convulsant, anti-inflammatory, analgesic, Anti-parasitic, anti-lipemic, anti-histaminic, anti-depressant, anti-psychotic, anti-emetic, anti-diabetic, anti-thrombotic, Anti-viral, anti-hypertensive, and Haemorheologic; animal health products, such as anti-tick, anti-parasitic, analgesic, anabolic steroids, female sex hormone, insecticide, and NSAID; and specialty biocides and antimicrobial actives, as well as additives for leather, paint…
Quarterly results
Consolidated figures in ₹ crores
| Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | |
|---|---|---|---|---|---|
| Sales | 371 | 316 | 491 | 517 | 400 |
| Operating profit | 25 | 7 | 83 | 105 | 37 |
| Net profit | -22 | -35 | -6 | 14 | -7 |
| EPS (₹) | -1.82 | -2.83 | -0.48 | 1.17 | -0.60 |
Peers in Drug Manufacturers - Specialty & Generic
Data for information only, not investment advice. Prices end of day.